Get started
Vicore Pharma Holding AB logo

VCRE

NASDAQ

Vicore Pharma Holding AB

SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Follow + get alerts
Website

Vicore Pharma Holding AB (VCRE) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 2 wire items for VCRE, including 2 SEC filings. The most recent was published Nov 5, 2026.

Vicore Pharma is a clinical-stage biopharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The company's lead program, buloxibutid, is an oral small-molecule angiotensin II type 2 receptor agonist, which received Orphan Drug and Fast Track designations from the United States Food and Drug Administration and is currently being investigated in the global 52-week Phase 2b ASPIRE trial in IPF. Vicore Pharma is publicly listed on Nasdaq Stockholm (VICO) and Nasdaq US (VCRE). www.vicorepharma.

News · 26 weeks2+100%
2026-05-10: 02026-05-17: 02026-05-24: 02026-05-31: 02026-06-07: 02026-06-14: 02026-06-21: 02026-06-28: 02026-07-05: 02026-07-12: 02026-07-19: 02026-07-26: 02026-08-02: 02026-08-09: 02026-08-16: 02026-08-23: 02026-08-30: 02026-09-06: 02026-09-13: 02026-09-20: 02026-09-27: 02026-10-04: 02026-10-11: 02026-10-18: 02026-10-25: 02026-11-01: 2
2026-05-102026-11-01
Mix290d
  • SEC Filings2(100%)
Activity · 52 weeks22 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news

Latest news

2 items

VCRE FAQ

6 questions
  • What does Vicore Pharma Holding AB do?
    Vicore Pharma is a clinical-stage biopharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The company's lead program, buloxibutid, is an oral small-molecule angiotensin II type 2 receptor agonist, which received Orphan Drug and Fast Track designations from the United States Food and Drug Administration and is currently being investigated in the global 52-week Phase 2b ASPIRE trial in IPF. Vicore Pharma is publicly listed on Nasdaq Stockholm (VICO) and Nasdaq...
  • What is the latest news on VCRE?
    In the last 30 days Quantisnow tracked 2 wire items for VCRE: 2 SEC filings. The most recent was published on November 5, 2026.
  • Where does VCRE stock trade?
    Vicore Pharma Holding AB (VCRE) is listed on NASDAQ.
  • What sector and industry is VCRE in?
    Vicore Pharma Holding AB operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.
  • What companies are similar to VCRE?
    Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare VCRE side-by-side with any of them on Quantisnow.
  • How can I track VCRE on Quantisnow?
    Quantisnow aggregates Vicore Pharma Holding AB's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow VCRE to receive live email and push alerts on every new disclosure.